Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 73.78
(3.49%)
INR 73.78
(3.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 504.21 Million INR | -3.29% |
| 2022 | 521.34 Million INR | -12.68% |
| 2021 | 597.03 Million INR | 54.65% |
| 2020 | 386.06 Million INR | 63.7% |
| 2019 | 235.83 Million INR | -36.49% |
| 2018 | 371.32 Million INR | 46.14% |
| 2017 | 254.09 Million INR | 1398.8% |
| 2016 | 16.95 Million INR | 31.46% |
| 2015 | 12.89 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2011 | 707.6 Million INR | -2.33% |
| 2010 | 724.44 Million INR | 56.69% |
| 2009 | 462.33 Million INR | -9.7% |
| 2008 | 511.97 Million INR | 0.99% |
| 2007 | 506.94 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 128.88 Million INR | 7.65% |
| 2023 Q4 | 119.72 Million INR | -7.74% |
| 2023 FY | 504.21 Million INR | -3.29% |
| 2023 Q2 | 148.9 Million INR | 40.72% |
| 2023 Q1 | 105.81 Million INR | -7.67% |
| 2023 Q3 | 129.77 Million INR | -12.85% |
| 2022 Q3 | 90.9 Million INR | -56.59% |
| 2022 Q2 | 209.42 Million INR | 96.82% |
| 2022 Q1 | 106.4 Million INR | -40.24% |
| 2022 FY | 521.34 Million INR | -12.68% |
| 2022 Q4 | 114.6 Million INR | 26.07% |
| 2021 Q3 | 218.1 Million INR | 82.05% |
| 2021 Q2 | 119.8 Million INR | 122.06% |
| 2021 Q4 | 178.04 Million INR | -18.36% |
| 2021 FY | 597.03 Million INR | 54.65% |
| 2021 Q1 | 53.95 Million INR | -58.74% |
| 2020 Q3 | 64.6 Million INR | -43.29% |
| 2020 FY | 386.06 Million INR | 63.7% |
| 2020 Q4 | 130.74 Million INR | 102.37% |
| 2020 Q1 | 76.8 Million INR | -24.83% |
| 2020 Q2 | 113.91 Million INR | 48.33% |
| 2019 Q4 | 102.17 Million INR | 94.05% |
| 2019 FY | 235.83 Million INR | -36.49% |
| 2019 Q1 | 30.19 Million INR | -64.54% |
| 2019 Q2 | 50.81 Million INR | 68.31% |
| 2019 Q3 | 52.65 Million INR | 3.61% |
| 2018 Q2 | 127.21 Million INR | 94.3% |
| 2018 Q1 | 65.47 Million INR | -35.84% |
| 2018 FY | 371.32 Million INR | 46.14% |
| 2018 Q4 | 85.15 Million INR | -8.92% |
| 2018 Q3 | 93.48 Million INR | -26.51% |
| 2017 Q3 | 157.85 Million INR | 503.96% |
| 2017 Q1 | 7.63 Million INR | -66.42% |
| 2017 Q4 | 102.05 Million INR | -35.35% |
| 2017 FY | 254.09 Million INR | 1398.8% |
| 2017 Q2 | 26.13 Million INR | 242.18% |
| 2016 Q2 | 3.9 Million INR | 446.22% |
| 2016 FY | 16.95 Million INR | 31.46% |
| 2016 Q3 | 4.04 Million INR | 3.72% |
| 2016 Q1 | 714 Thousand INR | 0.0% |
| 2016 Q4 | 22.74 Million INR | 462.25% |
| 2015 Q1 | 1.77 Million INR | 0.0% |
| 2015 FY | 12.89 Million INR | 0.0% |
| 2015 Q2 | - INR | -100.0% |
| 2015 Q3 | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2013 Q2 | - INR | 0.0% |
| 2013 Q3 | - INR | 0.0% |
| 2012 Q3 | 36.89 Million INR | 10.58% |
| 2012 Q2 | 33.36 Million INR | 0.0% |
| 2011 Q3 | 163.1 Million INR | -6.56% |
| 2011 FY | 707.6 Million INR | -2.33% |
| 2011 Q4 | 204.33 Million INR | 25.28% |
| 2011 Q2 | 174.55 Million INR | 0.0% |
| 2010 FY | 724.44 Million INR | 56.69% |
| 2009 FY | 462.33 Million INR | -9.7% |
| 2008 FY | 511.97 Million INR | 0.99% |
| 2008 Q4 | 135.72 Million INR | 0.0% |
| 2007 FY | 506.94 Million INR | 0.0% |
| 2007 Q4 | 128.76 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.896% |
| NATCO Pharma Limited | 40.02 Billion INR | 98.74% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 95.204% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 80.551% |
| Achyut Healthcare Limited | 61.36 Million INR | -721.612% |
| Ajanta Pharma Limited | 42.08 Billion INR | 98.802% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.602% |
| Alpa Laboratories Limited | 1.08 Billion INR | 53.631% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 99.175% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 96.108% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.824% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 89.349% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 93.454% |
| Brooks Laboratories Limited | 794.86 Million INR | 36.566% |
| Divi's Laboratories Limited | 78.45 Billion INR | 99.357% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.819% |
| Eris Lifesciences Limited | 20.09 Billion INR | 97.49% |
| FDC Limited | 19.42 Billion INR | 97.405% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.573% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 97.792% |
| Granules India Limited | 45.06 Billion INR | 98.881% |
| Gufic Biosciences Limited | 8.06 Billion INR | 93.749% |
| Hester Biosciences Limited | 3.04 Billion INR | 83.444% |
| Indoco Remedies Limited | 17.89 Billion INR | 97.182% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 96.064% |
| Ipca Laboratories Limited | 76.22 Billion INR | 99.339% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 75.84% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 51.673% |
| Laurus Labs Limited | 50.01 Billion INR | 98.992% |
| Lupin Limited | 200.1 Billion INR | 99.748% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.512% |
| Medicamen Biotech Limited | 1.79 Billion INR | 71.88% |
| Medico Remedies Limited | 1.44 Billion INR | 65.208% |
| Megasoft Limited | 373.95 Million INR | -34.834% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.383% |
| RPG Life Sciences Limited | 5.82 Billion INR | 91.337% |
| Sigachi Industries Limited | 3.98 Billion INR | 87.362% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | 33.257% |
| Unichem Laboratories Limited | 16.57 Billion INR | 96.958% |
| Wanbury Limited | 5.75 Billion INR | 91.241% |
| Windlas Biotech Limited | 6.3 Billion INR | 92.009% |
| ZIM Laboratories Limited | 3.67 Billion INR | 86.277% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.735% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 95.62% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 88.03% |
| Bal Pharma Limited | 3.39 Billion INR | 85.136% |
| Strides Pharma Science Limited | 40.51 Billion INR | 98.755% |
| Venus Remedies Limited | 5.91 Billion INR | 91.475% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 97.223% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 97.006% |
| Shilpa Medicare Limited | 11.51 Billion INR | 95.622% |
| Aarti Drugs Limited | 25.28 Billion INR | 98.006% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 97.62% |
| Suven Life Sciences Limited | 116.92 Million INR | -331.215% |
| Ind-Swift Limited | 5.02 Billion INR | 89.965% |
| Valiant Laboratories Limited | 1.82 Billion INR | 72.305% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 98.553% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 95.928% |
| Themis Medicare Limited | 3.81 Billion INR | 86.792% |
| Hikal Limited | 17.84 Billion INR | 97.175% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.525% |
| Sequent Scientific Limited | 13.69 Billion INR | 96.319% |
| Novartis India Limited | 3.35 Billion INR | 84.952% |
| Wockhardt Limited | 27.89 Billion INR | 98.192% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 99.248% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -25.943% |
| Neuland Laboratories Limited | 15.58 Billion INR | 96.765% |
| Morepen Laboratories Limited | 17.01 Billion INR | 97.037% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 67.338% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 86.321% |